Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations.

The perinatal period in schizophrenia is associated with high risk of psychotic relapse and pregnancy/child outcomes. The extent to which antipsychotics may potentially affect the fetus or the child development is unclear and debated. Even though guidelines have been developed, there is a lack of consensual recommendations regarding the optimal strategy to manage schizophrenia during the perinatal period. This systematic review describes the current state of evidence with respect to the impact of recommended interventions for schizophrenia during the perinatal period, including childbearing age, pregnancy, and post-partum. It compares recent international treatment guidelines for this specific group of women. Last, this review presents a set of major points to be discussed with patients and relatives for shared-decision making and a summary of key recommendations from the international guidelines. Although treatment guidelines may be of significant help, discrepancies exist across them regarding the management of antipsychotics for schizophrenia women during the perinatal period. Shared decision-making and advance directives represent useful patient-centered approaches during this specific period. Further cohort-based evidence is needed to better identify maternal and fetal risks associated to antipsychotic treatment exposure.

Citation

Amaury Lefebvre, Arnaud Pouchon, Stéphanie Bioulac, Jasmina Mallet, Mircea Polosan, Clément Dondé. Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations. Expert opinion on pharmacotherapy. 2022 Aug;23(11):1337-1350

Mesh Tags

Substances

PMID: 35835161

search → result